Study shows that Aorfix™ Reduces Iliac Limb Occlusion Rates from 7.5% to 0%
London, UK, 15 April 2010 – Lombard Medical Technologies PLC (AIM: LMT), announced today that Dr John Hardman has presented data this week at the 32nd International Charing Cross Symposium on the use of Aorfix™ in patients with tortuous iliac anatomy. The study was performed at the Royal United Hospital in Bath, UK.
The aim of the study was to evaluate the use of Lombard Medical’s Aorfix™ Stent Graft on the rate of iliac limb occlusion. The study had two arms, a control group and a study group. Aorfix™ was used in the study group only.
The control group included 93 patients, 12 of whom were considered to be severely angulated or required adjunctive stenting (12.9%). 7 patients in the control group developed iliac limb occlusions (7.5% occlusion rate), and 5 of these 7 patients required an additional intervention during the first two weeks post procedure.
The study group included 168 patients, 25 of whom were considered to be severely angulated (14.8%). Iliac limb occlusions were eliminated completely in this group (0% occlusion rate). The Aorfix™ stent graft was utilized in 40 of the most severely angulated cases in the study group.
Dr Hardman concluded his presentation by stating that:
“In our experience, having Aorfix™ available allows us to treat more patients with an endovascular approach. Furthermore, we have seen a dramatic improvement in our iliac limb occlusion rates when utilizing the Aorfix™ stent graft.”
- Ends -
About Lombard Medical
Lombard Medical Technologies PLC (AIM: LMT), is a medical device company focused on device solutions for the $1 billion dollar abdominal aortic aneurysm (AAA) repair market. AAA’s are a balloon-like enlargement of the aorta which, if left untreated, may rupture and cause death. Approximately 4.5 million people are living with AAA’s in the developed world and each year 600,000 new cases are diagnosed. The market for endovascular stent grafts for this application is expected to grow to $1.6 billion by 2015. The Company’s lead product, Aorfix™, is an endovascular stent graft which has been specifically designed to solve the problems that exist in treating complex tortuous anatomy which is often present in advanced AAA disease. Aorfix™ is currently being commercialised in the EU, with a pivotal clinical trial ongoing in the USA.
The Company is headquartered in Oxfordshire, with operations in Ayrshire and Phoenix, USA.
Further background on the Company can be found at www.lombardmedical.com.
For further information:
Lombard Medical Technologies PLC
John Rush, Chief Executive Officer
Tim Hall, Finance Director
Tel: 01235 750 800
Evolution Securities Limited
Barry Saint
Tel : 020 7071 4300
Financial Dynamics
Jonathan Birt
Tel : 020 7831 3113